All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.

The ALL Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your ALL Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
2024-06-17T14:22:47.000Z

U.S. FDA approves blinatumomab as consolidation for adult and pediatric patients with CD19+ B-ALL, irrespective of MRD status

Jun 17, 2024
Share:
Learning objective: After reading this article, learners will be able to cite a new clinical development in ALL.

On June 14, 2024, the U.S. Food and Drug Administration (FDA) approved blinatumomab for the treatment of adult and pediatric patients aged 1 month or older who have CD19-positive, Philadelphia chromosome (Ph)-negative B-cell precursor acute lymphoblastic leukemia (B-ALL) in the consolidation phase of multiphase chemotherapy, irrespective of measurable residual disease status.1 The decision is based primarily on data from the ECOG-ACRIN E1910 study (NCT02003222), a phase III randomized, controlled trial in adult patients with newly diagnosed, Ph-negative B-ALL, as well as data from study 20120215 (NCT02393859), a randomized, controlled, open-label, multicenter trial including pediatric and young adult patients with Ph-negative BCP ALL.1

Key data

In the ECOG-ACRIN E1910 study, eligible patients in hematologic complete remission (CR) or CR with incomplete peripheral blood count recovery (CRi) following induction and intensification chemotherapy were randomized 1:1 to receive a consolidation regimen of multiple blinatumomab monotherapy cycles plus multiple cycles of intensive chemotherapy (n = 112) or intensive chemotherapy alone (n = 112).1

  • Addition of blinatumomab to multiphase consolidation chemotherapy resulted in superior overall survival (OS) vs chemotherapy alone; 3-year OS was 84.8% (95% confidence interval [CI], 76.3–90.4) vs 69% (95% CI, 58.7–77.2) in the blinatumomab and chemotherapy arms, respectively.
  • At a median follow-up of 4.5 years, the 5-year OS was 82.4 % (95% CI, 73.7–88.4) in the blinatumomab arm and 62.5 % (95% CI, 52.0–71.3) in the chemotherapy arm.

In study 20120215, patients aged >28 days and <18 years were randomized 1:1 to receive blinatumomab or the IntReALLHR2010 HC3 intensive combination chemotherapy as the third consolidation cycle.1

  • The 5-‑year OS was 78.4% (95% CI, 64.2–87.4) vs 41.4% (95% CI, 26.3–55.9) for the blinatumomab and chemotherapy arms, respectively.
  • The 5-year relapse-free survival was 61.1% (95% CI, 46.3–72.9) with blinatumomab and 27.6% (95% CI, 16.2–40.3) with chemotherapy.

Conclusion 

This FDA approval marks an important clinical development for this patient population, allowing treatment with blinatumomab irrespective of MRD status, redefining the standard of care for patients with B-ALL.1,2





  1. U.S. Food & Drug Administration. FDA approves blinatumomab as consolidation for CD19-positive Philadelphia chromosome-negative B-cell precursor acute lymphoblastic leukemia. https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-blinatumomab-consolidation-cd19-positive-philadelphia-chromosome-negative-b-cell. Published Jun 14, 2024. Accessed Jun 17, 2024.
  2. OncLive. FDA approves blinatumomab for CD19+ B-ALL in the consolidation Phase. https://www.onclive.com/view/fda-approves-blinatumomab-for-cd19-b-all-in-the-consolidation-phase. Published Jun 14, 2024. Accessed Jun 17, 2024.

Newsletter

Subscribe to get the best content related to ALL delivered to your inbox